DOCSLIB.ORG

Ocular Alterations in Alopecia Areata

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ocular Alterations in Alopecia Areata Ocular alterations in SANTI MARIA RECUPERO, SOLMAZ ABDOLRAHIMZADEH, MARCO DE alopecia areata DOMINIC IS, ROBERTO MOLLO, ISABELLA CARBONI, LUC REZIA ROTA, STEFANO CALVIERI Abstract this study was to investigate the prevalence and appearance of the ocular changes occurring in Purpose To determine the ocular alterations AA. occurring in alopecia areata with regard to the lens and fundus. Methods Seventy-five patients with alopecia Patients and methods areata were examined. Seventy healthy control patients unaffected by skin, ocular or systemic Seventy-five patients (25 men, 50 women; age disorders were also studied. range 7-61 years) with AA who were seen for Results Symptomless punctate lens opacities dermatological reasons at the Dermatology were found in 38 (51%) patients, whereas only Institute of the University of Rome 'La 2 (3%) control patients had similar lens Sapienza' were referred for ophthalmological changes. Fundus alterations were found in 31 examination as part of the study and solely (41 %) cases of alopecia areata and in only 16 because of the presence of AA. All patients were (23%) controls. subjected to the following tests: visual acuity, Conclusions These ocular alterations and their applanation tonometry, anterior segment prevalence are reported and some theories biomicroscopy with study of the lens and regarding the possible aetiopathogenetic fundus ophthalmoscopy after full mechanisms are discussed. pharmacological mydriasis. Seventy healthy control patients (25 men, 45 women; chosen to be comparable in age to the AA patients) Key words Aetiopathogenetic mechanisms, unaffected by skin, ocular or systemic disorders Alopecia areata, Fundus alterations, Punctate were also studied. The cases of AA were lens opacities divided into groups designated as: universalis (complete loss of scalp and body hair), totalis (complete loss of scalp hair) and areata Alopecia areata patients have asymptomatic, (incomplete loss of the hair from the scalp, S.M. Recupero isolated areas of hair loss usually of the scalp, beard or other body areas). S. Abdolrahimzadeh though any area of the body may be involved. M. De Dominicis Normal hair growth usually resumes after a R. Mollo Istituto di Oftal mologi a variable period but at times spontaneous Results Universita di Roma remission does not occur and loss of hair The personal history of various diseases in the 'La Sapienza' extends to all of the scalp (alopecia totalis) or Rome, Italy AA patients is shown in Table 1. In 24 (32%) the entire body (alopecia universalis). Many there was thyroid pathology and in 17 (23%) theories have been advanced for the obscure I. Carboni there was a history of atopic dermatitis. Two L. Rota pathogenesis behind this condition, but recently patients suffered from vitiligo, 3 had anaemia S. Calvieri there seems to be strong evidence for an (microcytaemia), 3 were affected with diabetes Istituto di Dermatologia autoimmune mechanism with mediation of T Universita di Roma mellitus, 1 had Down's syndrome and 15 cells. 1 'La Sapienza' patients (20%) had neuropsychiatric problems. Rome, Italy Ocular alterations have previously been The patients in the control group were reported in alopecia areata (AA). Indeed, there unaffected by skin, ocular or systemic disorders. Professor S.M. Recupero � Istituto di Of tal mologia have been various reports of lens alterations, Even though they were chosen to be of ages Universita di Roma from cases of cataracf!-4 to minor punctate comparable to the patients with AA, statistical 'La Sapienza' opacities.5-7 However, there are contrasting analysis with Student's t-test showed a lower Policlinico Umberto I opinions as to the prevalence of these lens (t = 2.3; d.f. = 144; p = 0.02) mean age in the AA 1-00161 Rome, Italy changes. Involvement of the chorioretina has group (30.4 years, SD = 13.1) compared with the Tel: +3906 490296 9 Fax: +3906 4457706 also been reported in AA,5.8. but the control group (36.2 years, SD = 17.2), significance and aetiopathogenesis of both the Table 2 shows the various modalities of Received: 4 January 1999 lens changes and the fundus alterations in treatment undergone by the AA patients in the Accepted in revised form: patients with AA is still obscure. The purpose of past. 24 June 1999 Eye (1999) 13. 643-M6 © 1999 Royal College of Ophthalmologists 643 Table 3. Details of alopecia areata and control patients and prevalence Associated diseases in the alopecia areata patients Table 1. of lens opacities Pathology No. of patients (%) No. of Lens changes Thyroid pathology 24 (32%) Diagnosis patients M/F present Atopic dermatitis 17 (23%) Alopecia universalis 16 9/7 14 (88%) Vitiligo 2 (3%) Alopecia totalis 9 1/8 4 (44%) Diabetes mellitus 3 (4%) Alopecia areata 50 15/35 20 (40%) Neuropsychiatric problems 15 (20%) Total AA patients 75 25/50 38 (51%) Anaemia 3 (4%) Down's syndrome 1 (1%) Control patients 70 25/45 2 (3%) There were no significant relationships between In our group of AA patients 17 also suffered from ocular alterations and the duration of illness, age or sex atopic dermatitis, 8 of whom presented punctate lens of the patients. Asymptomatic punctate lens opacities opacities. Cataract associated with atopic dermatitis is were found in 38 (51%) affected patients and 2 (3%) characteristic; it nearly always begins in the posterior control patients. Furthermore, the opacities were subcapsular area near the pole, growing forward and encountered in 14 (88%), 4 (44%) and 20 (40%) patients peripherally in a successive process occurring in the with alopecia universalis, totalis and areata, respectively anterior subcapsular zone. It has been reported in (Table 3). Details of the location of the lens opacities are approximately 8-10% of patients with an average age of shown in Table 4. The fundus alterations were, in the 22-25.5 years.lO,n Furthermore, in the description of the majority of cases, at the extreme periphery of the retina patients studied by Cowan and Klauder10 'tiny, dotlike and these are detailed in Table 5. They were found in 31 or punctate' opacities were described in about 10% of (41%) patients with AA and in 16 (23%) control patients. eyes. These opacities do not seem to be clinically There was no difference in their prevalence in the three different from the punctate opacities observed in AA forms of AA. patients, and therefore an association with atopic dermatitis cannot be strictly ruled out. Thyroid pathology with the presence of anti-thyroid antibodies Discussion was observed in 24 patients, 9 of whom had punctate There is a high frequency of ocular alterations in AA, but lens opacities. The association of AA with the first to be reported was the development of cataract, autoantibodies, especially those against thyroid which is, nevertheless, quite rare? Two other reports components, has been widely discussed in view of the 1 were subsequently published.3,4 However, in these cases debated autoimmune pathogenesis of AA. 2-16 Indeed, a there could have been other possible causes of cataract: recent article by Gilhar et aI./ has provided strong long-standing atopic dermatitis, long-term systemic evidence that the disease has an autoimmune corticosteroid therapy and vitiligo. Also, patients had pathogenesis. Its possible association with thyroid reached their middle to advanced years of life where the pathology needs to be clarified. association may be questionable. The history regarding previous systemic Our study did not reveal any cases of cataract in the corticosteroid treatment was not reported with precision AA patients but we found a prevalence of symptomless by the patients with AA. The majority did not have any punctate lens opacities which was significantly higher documentation of previous consultations in various medical settings. There had been previous therapy with than in the control population (X2 = 41.43; d.£. = 1; P < 0.0001). steroids but this was mainly local (scalp) applications Some authors have reported similar results5 while and in some cases patients claimed that systemic steroids others did not find significant lens changes.6,7 This, we had been administered for short periods (not exceeding 6 believe, is mainly due to the control population taken months). The treatment protocol administered at the into consideration in the various reports, which in our dermatology clinic in 22 patients consisted of deflazacort study was unaffected by other skin, ocular or systemic 15 mg t.i.d. and the ophthalmic examination was diseases that could influence the outcome of the results. performed at a maximum of 1 month from the initiation We did not find any association with the duration of of this treatment. We encountered symptomless punctate illness but there was a higher prevalence of lens opacities opacities in 11 patients undergoing this therapy. It has in alopecia universalis compared with the totalis and been demonstrated that patients receiving 16 mg of prednisone or its equivalent daily for over a year are areata forms (l = 11.10; d.f. = 2; p = 0.0038). extremely likely to develop posterior subcapsular Table 2. Treatment in the alopecia areata patients cataractsy,18 To our knowledge, the patients in our No. of patients with study had not received this dose of steroids and the Total no. of punctate lens duration of treatment had also been less than 6 months. Treatment patients opacities (%) Furthermore, it can be argued that the symptomless Systemic corticosteroids 22 11 (50%) punctate opacities seen in our patients were not cataracts Local (scalp) treatment 56 21 (38%) arising after steroid treatment as described in the Cyclosporine 7 3 (43%) literature. The punctate lens opacities were located in the PUVA 4 1 (25%) posterior subcapsular area in only 5 patients and again 644 Table 4. Type of lens opacities in alopecia areata and control patients Type of lens opacities (no. of patients) Diagnosis No.
Load more

Recommended publications
  • Pediatric and Adolescent Dermatology
    Pediatric and adolescent dermatology Management and referral guidelines ICD-10 guide • Acne: L70.0 acne vulgaris; L70.1 acne conglobata; • Molluscum contagiosum: B08.1 L70.4 infantile acne; L70.5 acne excoriae; L70.8 • Nevi (moles): Start with D22 and rest depends other acne; or L70.9 acne unspecified on site • Alopecia areata: L63 alopecia; L63.0 alopecia • Onychomycosis (nail fungus): B35.1 (capitis) totalis; L63.1 alopecia universalis; L63.8 other alopecia areata; or L63.9 alopecia areata • Psoriasis: L40.0 plaque; L40.1 generalized unspecified pustular psoriasis; L40.3 palmoplantar pustulosis; L40.4 guttate; L40.54 psoriatic juvenile • Atopic dermatitis (eczema): L20.82 flexural; arthropathy; L40.8 other psoriasis; or L40.9 L20.83 infantile; L20.89 other atopic dermatitis; or psoriasis unspecified L20.9 atopic dermatitis unspecified • Scabies: B86 • Hemangioma of infancy: D18 hemangioma and lymphangioma any site; D18.0 hemangioma; • Seborrheic dermatitis: L21.0 capitis; L21.1 infantile; D18.00 hemangioma unspecified site; D18.01 L21.8 other seborrheic dermatitis; or L21.9 hemangioma of skin and subcutaneous tissue; seborrheic dermatitis unspecified D18.02 hemangioma of intracranial structures; • Tinea capitis: B35.0 D18.03 hemangioma of intraabdominal structures; or D18.09 hemangioma of other sites • Tinea versicolor: B36.0 • Hyperhidrosis: R61 generalized hyperhidrosis; • Vitiligo: L80 L74.5 focal hyperhidrosis; L74.51 primary focal • Warts: B07.0 verruca plantaris; B07.8 verruca hyperhidrosis, rest depends on site; L74.52 vulgaris (common warts); B07.9 viral wart secondary focal hyperhidrosis unspecified; or A63.0 anogenital warts • Keratosis pilaris: L85.8 other specified epidermal thickening 1 Acne Treatment basics • Tretinoin 0.025% or 0.05% cream • Education: Medications often take weeks to work AND and the patient’s skin may get “worse” (dry and red) • Clindamycin-benzoyl peroxide 1%-5% gel in the before it gets better.
    [Show full text]
  • Herb Lotions to Regrow Hair in Patients with Intractable Alopecia Areata Hideo Nakayama*, Ko-Ron Chen Meguro Chen Dermatology Clinic, Tokyo, Japan
    Clinical and Medical Investigations Research Article ISSN: 2398-5763 Herb lotions to regrow hair in patients with intractable alopecia areata Hideo Nakayama*, Ko-Ron Chen Meguro Chen Dermatology Clinic, Tokyo, Japan Abstract The history of herbal medicine in China goes back more than 1,000 years. Many kinds of mixtures of herbs that are effective to diseases or symptoms have been transmitted from the middle ages to today under names such as Traditional Chinese Medicine (TCM) in China and Kampo in Japan. For the treatment of severe and intractable alopecia areata, such as alopecia universalis, totalis, diffusa etc., herb lotions are known to be effective in hair regrowth. Laiso®, Fukisin® in Japan and 101® in China are such effective examples. As to treat such cases, systemic usage of corticosteroid hormones are surely effective, however, considering their side effects, long term usage should be refrained. There are also these who should refrain such as small children, and patients with peptic ulcers, chronic infections and osteoporosis. AL-8 and AL-4 were the prescriptions removing herbs which are not allowed in Japanese Pharmacological regulations from 101, and salvia miltiorrhiza radix (SMR) is the most effective herb for hair growth, also the causation to produce contact sensitization. Therefore, the mechanism of hair growth of these herb lotions in which the rate of effectiveness was in average 64.8% on 54 severe intractable cases of alopecia areata, was very similar to DNCB and SADBE. The most recommended way of developing herb lotion with high ability of hairgrowth is to use SMR but its concentration should not exceed 2%, and when sensitization occurs, the lotion should be changed to Laiso® or Fukisin®, which do not contain SMR.
    [Show full text]
  • Hypertrichosis in Alopecia Universalis and Complex Regional Pain Syndrome
    NEUROIMAGES Hypertrichosis in alopecia universalis and complex regional pain syndrome Figure 1 Alopecia universalis in a 46-year- Figure 2 Hypertrichosis of the fifth digit of the old woman with complex regional complex regional pain syndrome– pain syndrome I affected hand This 46-year-old woman developed complex regional pain syndrome (CRPS) I in the right hand after distor- tion of the wrist. Ten years before, the diagnosis of alopecia areata was made with subsequent complete loss of scalp and body hair (alopecia universalis; figure 1). Apart from sensory, motor, and autonomic changes, most strikingly, hypertrichosis of the fifth digit was detectable on the right hand (figure 2). Hypertrichosis is common in CRPS.1 The underlying mechanisms are poorly understood and may involve increased neurogenic inflammation.2 This case nicely illustrates the powerful hair growth stimulus in CRPS. Florian T. Nickel, MD, Christian Maiho¨fner, MD, PhD, Erlangen, Germany Disclosure: The authors report no disclosures. Address correspondence and reprint requests to Dr. Florian T. Nickel, Department of Neurology, University of Erlangen-Nuremberg, Schwabachanlage 6, 91054 Erlangen, Germany; [email protected] 1. Birklein F, Riedl B, Sieweke N, Weber M, Neundorfer B. Neurological findings in complex regional pain syndromes: analysis of 145 cases. Acta Neurol Scand 2000;101:262–269. 2. Birklein F, Schmelz M, Schifter S, Weber M. The important role of neuropeptides in complex regional pain syndrome. Neurology 2001;57:2179–2184. Copyright © 2010 by
    [Show full text]
  • Xeljanz Shows Promise As Treatment for Alopecia Areata in Adolescents
    Xeljanz shows promise as treatment for alopecia areata in adole... http://www.healio.com/dermatology/hair-nails/news/online/{0c... IN THE JOURNALS Xeljanz shows promise as treatment for alopecia areata in adolescents Craiglow BG, et al. J Am Acad Dermatol. 2016;doi:10.1016/j.jaad.2016.09.006. November 3, 2016 Treatment with Xeljanz in adolescents with alopecia areata resulted in significant hair regrowth for the majority of the patients, with mild adverse events, according to recently published study results. Brent A. King, MD, PhD, assistant professor of dermatology, Yale School of Medicine, and colleagues studied 13 adolescent patients (median age 15 years; 77% male) with alopecia areata treated with Xeljanz (tofacitinib, Pfizer) between July 2014 and May 2016 at a tertiary care center clinic. They used the Severity of Alopecia Tool (SALT) to measure severity of disease, and laboratory monitoring, physical examinations and review of systems to measure adverse events. The patients were treated for a median duration of 5 months. Patient age ranged from 12 to 17 years at time of treatment initiation. Six patients had alopecia universalis, one had alopecia totalis and six had alopecia areata. The median duration of disease before beginning therapy of Brent A. King 8 years. All patients received tofacitinib 5 mg twice daily. One patient who had complete regrowth over 5 months developed four 1- to 3-cm patches of alopecia, and received an increased dose of 10 mg in the morning and 5 mg in the evening, with full regrowth occurring again. Clinically significant hair growth was experienced by nine patients, and very minimal hair growth was experienced by three patients.
    [Show full text]
  • Hair That Does Not Grow: Loose Anagen Hair Syndrome Versus Short Anagen Hair Syndrome
    Central Annals of Pediatrics & Child Health Clinical Image *Corresponding author Norma E.Vázquez-Herrera, Hospital Zambrano Hellion Batallón San Patricio 112 Col. Real de San Agustín, San Hair That Does Not Grow: Pedro Garza García, México, Tel: 5281888880650; Email: Submitted: 03 March 2016 Loose Anagen Hair Syndrome Accepted: 29 April 2016 Published: 03 May 2016 Versus Short Anagen Hair Copyright © 2016 Vázquez-Herrera et al. Syndrome OPEN ACCESS Keywords Vázquez-Herrera NE1*, Sharma D2, Tosti A3 • Loose anagen hair syndrome • LAHS 1Departamen of MedicinaInterna, Tecnológico de Monterrey, México • Short anagen hair syndrome 2 Rutgers University, New Jersey Medical School, USA • SAHS 3 Department of Dermatology and Cutaneous Surgery, University of Miami, USA • Trichogram • Alopecia Abstract • Hair disorder • Pediatric hair loss Loose anagen hair syndrome (LAHS) is a hair disorder that is caused by defective • Painless extraction of hair anchorage of the hair shaft to the follicle and primarily affects children. Diagnosis is • Hair that will not grow made clinically by painless plucking of hair that does not grow long and confirmed • Short hair in child by a trichogram with distrophic anagen hairs. Short anagen hair syndrome (SAHS) is another hair condition in which anagen phase has a short duration and as a result, patients present with very short hair and often complain of increased shedding. In this second pathology, pull test shows extraction of telogen hairs with a pointed tip. Both of these diseases must be considered in pediatric patients that present with a complaint of hair that does not grow long. CLINICAL IMAGE encoding for companion layer keratin (K6HF) in patients with LAHS and wooly hair syndrome.
    [Show full text]
  • An Unpleasant Reality with Interferon Alfa-2B and Ribavirin Treatment for Hepatitis C
    Advanced Research in Gastroenterology & Hepatology Case Report Adv Res Gastroentero Hepatol Volume 1 Issue 3 - January 2016 Copyright © All rights are reserved by Parveen Malhotra Alopecia Universalis- An Unpleasant Reality with Interferon Alfa-2b and Ribavirin Treatment for Hepatitis C Parveen Malhotra*, Naveen Malhotra, Vani Malhotra, Ajay Chugh, Abhishek Chaturvedi, Parul Chandrika and Ishita Singh Department of Medical Gastroenterology, Anaesthesiology, Obstetrics & Gynaecology, Pt.B.D.S. Post Graduate Institute of Medical Sciences (PGIMS), India Submission: January 01, 2016; Published: January 29, 2016 *Corresponding author: Parveen Malhotra, Department of Medical Gastroenterology, PGIMS, 128/19, Civil Hospital Road, Rohtak– 124001 (Haryana) India, Tel: 919671000017; Email: Abstract Numerous cutaneous side effects of combination Pegylated interferon alfa-2b (PEG-IFN) and ribavirin (RBV) therapy have been reported. Although cases alopecia areata (AA) associated with PEG-IFN/RBV therapy have been reported in the literature, but alopecia universalis is uncommon entity. We have treated up till now around 3500 patients suffering from this disease with Pegylated Interferon-2b and ribavirin, as oral directly acting antivirals has been recently launched in India. Out of these 3500 patients, 1470 (42%) patients developed alopecia during various stages of treatment, some even after stopping of treatment. Five patients developed Alopecia Universalis (AU) while undergoing the treatment which makes prevalence rate of 14% in total of 3500 but if we calculate prevalence of Alopecia Universalis in patients who developed alopecia on treatment, it increases to 34%. Now the good thing is that we have already entered the phase of Interferon free treatment in India, thus patients will get rid of these frustrating side effects like AA and AU which undermines the importance of successful treatment after achievement of sustained virological response.
    [Show full text]
  • Alopecia Areata: Evidence-Based Treatments
    Alopecia Areata: Evidence-Based Treatments Seema Garg and Andrew G. Messenger Alopecia areata is a common condition causing nonscarring hair loss. It may be patchy, involve the entire scalp (alopecia totalis) or whole body (alopecia universalis). Patients may recover spontaneously but the disorder can follow a course of recurrent relapses or result in persistent hair loss. Alopecia areata can cause great psychological distress, and the most important aspect of management is counseling the patient about the unpredictable nature and course of the condition as well as the available effective treatments, with details of their side effects. Although many treatments have been shown to stimulate hair growth in alopecia areata, there are limited data on their long-term efficacy and impact on quality of life. We review the evidence for the following commonly used treatments: corticosteroids (topical, intralesional, and systemic), topical sensitizers (diphenylcyclopropenone), psor- alen and ultraviolet A phototherapy (PUVA), minoxidil and dithranol. Semin Cutan Med Surg 28:15-18 © 2009 Elsevier Inc. All rights reserved. lopecia areata (AA) is a chronic inflammatory condition caus- with AA having nail involvement. Recovery can occur spontaneously, Aing nonscarring hair loss. The lifetime risk of developing the although hair loss can recur and progress to alopecia totalis (total loss of condition has been estimated at 1.7% and it accounts for 1% to 2% scalp hair) or universalis (both body and scalp hair). Diagnosis is usu- of new patients seen in dermatology clinics in the United Kingdom ally made clinically, and investigations usually are unnecessary. Poor and United States.1 The onset may occur at any age; however, the prognosis is linked to the presence of other immune diseases, family majority (60%) commence before 20 years of age.2 There is equal history of AA, young age at onset, nail dystrophy, extensive hair loss, distribution of incidence across races and sexes.
    [Show full text]
  • Hair and Nail Disorders
    Hair and Nail Disorders E.J. Mayeaux, Jr., M.D., FAAFP Professor of Family Medicine Professor of Obstetrics/Gynecology Louisiana State University Health Sciences Center Shreveport, LA Hair Classification • Terminal (large) hairs – Found on the head and beard – Larger diameters and roots that extend into sub q fat LSUCourtesy Health of SciencesDr. E.J. Mayeaux, Center Jr., – M.D.USA Hair Classification • Vellus hairs are smaller in length and diameter and have less pigment • Intermediate hairs have mixed characteristics CourtesyLSU Health of E.J. Sciences Mayeaux, Jr.,Center M.D. – USA Life cycle of a hair • Hair grows at 0.35 mm/day • Cycle is typically as follows: – Anagen phase (active growth) - 3 years – Catagen (transitional) - 2-3 weeks – Telogen (preshedding or rest) about 3 Mon. • > 85% of hairs of the scalp are in Anagen – Lose 75 – 100 hairs a day • Each hair follicle’s cycle is usually asynchronous with others around it LSU Health Sciences Center – USA Alopecia Definition • Defined as partial or complete loss of hair from where it would normally grow • Can be total, diffuse, patchy, or localized Courtesy of E.J. Mayeaux, Jr., M.D. CourtesyLSU of Healththe Color Sciences Atlas of Family Center Medicine – USA Classification of Alopecia Scarring Nonscarring Neoplastic Medications Nevoid Congenital Injury such as burns Infectious Systemic illnesses Genetic (male pattern) (LE) Toxic (arsenic) Congenital Nutritional Traumatic Endocrine Immunologic PhysiologicLSU Health Sciences Center – USA General Evaluation of Hair Loss • Hx is
    [Show full text]
  • Case of Persistent Regrowth of Blond Hair in a Previously Brunette Alopecia Areata Totalis Patient
    Case of Persistent Regrowth of Blond Hair in a Previously Brunette Alopecia Areata Totalis Patient Karla Snider, DO,* John Young, MD** *PGYIII, Silver Falls Dermatology/Western University, Salem, OR **Program Director, Dermatology Residency Program, Silver Falls Dermatology, Salem, OR Abstract We present a case of a brunette, 64-year-old female with no previous history of alopecia areata who presented to our clinic with diffuse hair loss over the scalp. She was treated with triamcinolone acetonide intralesional injections and experienced hair re-growth of initially white hair that then partially re-pigmented to blond at the vertex. Two years following initiation of therapy, she continued to have blond hair growth on her scalp with no dark hair re-growth and no recurrence of alopecia areata. Introduction (CBC), comprehensive metabolic panel (CMP), along the periphery of the occipital, parietal and Alopecia areata (AA) is a fairly common thyroid stimulating hormone (TSH) test and temporal scalp), sisaipho pattern (loss of hair in autoimmune disorder of non-scarring hair loss. antinuclear antibody (ANA) test. All values were the frontal parietotemporal scalp), patchy hair unremarkable, and the ANA was negative. The loss (reticular variant) and a diffuse thinning The disease commonly presents as hair loss from 2 any hair-bearing area of the body. Following patient declined a biopsy. variant. Often, “exclamation point hairs” can be hair loss, it is not rare to see initial growth of A clinical diagnosis of alopecia areata was seen in and around the margins of the hair loss. depigmented or hypopigmented hair in areas made. The patient was treated with 5.0 mg/mL The distal ends of these hairs are thicker than the proximal ends, and they are a marker of active of regrowth in the first anagen cycle.
    [Show full text]
  • Loose Anagen Syndrome in a 2-Year-Old Female: a Case Report and Review of the Literature
    Loose Anagen Syndrome in a 2-year-old Female: A Case Report and Review of the Literature Mathew Koehler, DO,* Anne Nguyen, MS,** Navid Nami, DO*** * Dermatology Resident, 2nd year, Opti-West/College Medical Center, Long Beach, CA ** Medical Student, 4th Year, Western University of Health Sciences, College of Osteopathic Medicine, Pomona, CA *** Dermatology Residency Program Director, Opti-West/College Medical Center, Long Beach, CA Abstract Loose anagen syndrome is a rare condition of abnormal hair cornification leading to excessive and painless loss of anagen hairs from the scalp. The condition most commonly affects young females with blonde hair, but males and those with darker hair colors can be affected. Patients are known to have short, sparse hair that does not need cutting, and hairs are easily and painlessly plucked from the scalp. No known treatment exists for this rare disorder, but many patients improve with age. Case Report neck line. The patient had no notable medical Discussion We present the case of a 27-month-old female history and took no daily medicines. An older Loose anagen syndrome is an uncommon presenting to the clinic with a chief complaint brother and sister had no similar findings. She condition characterized by loosely attached hairs of diffuse hair loss for the last five months. The was growing well and meeting all developmental of the scalp leading to diffuse thinning with poor mother stated that she began finding large clumps milestones. The mother denied any major growth, thus requiring few haircuts. It was first of hair throughout the house, most notably in the traumas, psychologically stressful periods or any described in 1984 by Zaun, who called it “syndrome child’s play area.
    [Show full text]
  • Trachyonychia Associated with Alopecia Areata and Secondary Onychomycosis
    TRACHYONYCHIA ASSOCIATED WITH ALOPECIA AREATA AND SECONDARY ONYCHOMYCOSIS Jose L. Anggowarsito Renate T. Kandou Department of Dermatovenereology Medical Faculty of Sam Ratulangi University Prof. Dr. R. D. Kandou Hospital Manado Email: [email protected] Abstract: Trachyonychia is an idiopathic nail inflammatory disorder that causes nail matrix keratinization abnormality, often found in children, and associated with alopecia areata, psoriasis, atopic dermatitis, or nail lichen planus. Trachyonychia could be a manifestation of associated pleomorphic or idiopathic disorders; therefore, it may occur without skin or other systemic disorders. There is no specific diagnostic criteria for tracyonychia. A biopsy is needed to determine the definite pathologic diagnosis for nail matrix disorder; albeit, in a trachyonychia case it is not entirely necessary. Trachyonychia assessment is often unsatisfactory and its management is focused primarily on the underlying disease. We reported an 8-year-old girl with twenty dystrophic nails associated with alopecia areata. Cultures of nail base scrapings were performed two times and the final impression was trichophyton rubrum. Conclusion: Based on the clinical examination and all the tests performed the diagnosis of this case was trachyonychia with twenty dystrophic nails associated with alopecia areata and secondary onychomycosis.The majority of trachyonychia cases undergo spontaneous improvement; therefore, a specific therapy seems unnecessary. Onychomycosis is often difficult to be treated. Eradication of the fungi is not always followed by nail restructure, especially if there has been dystrophy before the infection. Keywords: trachyonychia, alopecia areata, onychomycosis. Abstrak: Trakionikia adalah inflamasi kuku idiopatik yang menyebabkan gangguan keratinisasi matriks kuku, sering terjadi pada anak, dan terkait dengan alopesia areata, psoriasis, dermatitis atopik atau lichen planus kuku.
    [Show full text]
  • Dermatology Update
    12/6/19 Dermatology Update Lindy P. Fox, MD Professor of Clinical Dermatology Director, Hospital Consultation Service Department of Dermatology University of California, San Francisco [email protected] I have no conflicts of interest to disclose I may be discussing off-label use of medications 1 1 Outline • Principles of topical therapy • Chronic Urticaria • Alopecia • Acne in the adult • Perioral dermatitis • Sunscreens 2 2 1 12/6/19 Principles of Dermatologic Therapy Moisturizers and Gentle Skin Care • Moisturizers – Contain oil to seal the surface of the skin and replace the damaged water barrier – Petrolatum (Vaseline) is the premier and “gold standard” moisturizer – Additions: water, glycerin, mineral oil, lanolin – Some try to mimic naturally occurring ceramides (E.g. CeraVe) • Thick creams more moisturizing than pump lotions 3 Principles of Dermatologic Therapy Moisturizers and Gentle Skin Care • Emolliate skin – All dry skin itches • Gentle skin care – Soap to armpits, groin, scalp only – Short cool showers or tub soak for 15-20 minutes – Apply medications and moisturizer within 3 minutes of bathing or swimming 4 2 12/6/19 Principles of Dermatologic Therapy Topical Medications • The efficacy of any topical medication is related to: 1. The concentration of the medication 2. The vehicle 3. The active ingredient (inherent strength) 4. Anatomic location 5 Vehicles • Ointment (like Vaseline): – Greasy, moisturizing, messy, most effective. • Creams (vanish when rubbed in): – Less greasy, can sting, more likely to cause allergy (preservatives/fragrances).
    [Show full text]